{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T07:14:51Z","timestamp":1775200491157,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T00:00:00Z","timestamp":1619827200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","plefa.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Prostaglandins, Leukotrienes and Essential Fatty Acids"],"published-print":{"date-parts":[[2021,5]]},"DOI":"10.1016\/j.plefa.2021.102282","type":"journal-article","created":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T16:19:01Z","timestamp":1618330741000},"page":"102282","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Safety and Efficacy of Evacetrapib in Patients with Inadequately-controlled Hypercholesterolemia and High Cardiovascular Risk; A meta-analysis of Randomized Placebo-controlled Trials"],"prefix":"10.1016","volume":"168","author":[{"given":"Eshak I.","family":"Bahbah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed S.A.","family":"Shehata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Safwat Ibrahim","family":"Alnahrawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr","family":"Menshawey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed","family":"Fisal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Morsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Essam","family":"Gabr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Salah Abd","family":"Elbasit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.plefa.2021.102282_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/296417","article-title":"Dysfunctional High-Density Lipoprotein: an Innovative Target for Proteomics and Lipidomics","volume":"2015","author":"Salazar","year":"2015","journal-title":"Cholesterol"},{"key":"10.1016\/j.plefa.2021.102282_bib0002","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials","volume":"376","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaboration","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.plefa.2021.102282_bib0003","first-page":"169","article-title":"Familial Hypercholesterolemia","volume":"33","author":"Bouhairie","year":"2015","journal-title":"Cardiol Clin"},{"key":"10.1016\/j.plefa.2021.102282_bib0004","doi-asserted-by":"crossref","first-page":"a993","DOI":"10.1136\/bmj.a993","article-title":"Hypercholesterolaemia and its management","volume":"337","author":"Bhatnagar","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.plefa.2021.102282_bib0005","doi-asserted-by":"crossref","first-page":"7A","DOI":"10.1016\/0002-9149(90)90562-F","article-title":"High-density lipoprotein, low-density lipoprotein and coronary artery disease","volume":"66","author":"Wilson","year":"1990","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.plefa.2021.102282_bib0006","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.292.3.331","article-title":"Efficacy and Safety of Statin Therapy in Children With Familial Hypercholesterolemia","volume":"292","author":"Wiegman","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.plefa.2021.102282_bib0007","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.tcm.2015.01.009","article-title":"PCSK9 inhibition in patients with hypercholesterolemia","volume":"25","author":"Desai","year":"2015","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.plefa.2021.102282_bib0008","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1056\/NEJMoa1609581","article-title":"Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease","volume":"376","author":"Lincoff","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.plefa.2021.102282_bib0009","doi-asserted-by":"crossref","first-page":"S201","DOI":"10.1194\/jlr.R800061-JLR200","article-title":"The role of plasma lipid transfer proteins in lipoprotein metabolism and atherogenesis","volume":"50","author":"Masson","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plefa.2021.102282_bib0010","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1111\/j.1476-5381.2012.02081.x","article-title":"Cardiovascular disease risk reduction by raising HDL cholesterol - current therapies and future opportunities","volume":"167","author":"Ali","year":"2012","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.plefa.2021.102282_bib0011","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of Torcetrapib in Patients at High Risk for Coronary Events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.plefa.2021.102282_bib0012","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.plefa.2021.102282_bib0013","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease","volume":"377","author":"Bowman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.plefa.2021.102282_bib0014","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1253\/circj.CJ-16-1325","article-title":"Efficacy and Safety of Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib Administered as Monotherapy in Japanese Patients With Primary Hypercholesterolemia","volume":"81","author":"Teramoto","year":"2017","journal-title":"Circ J"},{"key":"10.1016\/j.plefa.2021.102282_bib0015","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.plefa.2021.102282_bib0016","first-page":"1","article-title":"Handbook for Systematic Reviews of Interventions","volume":"520","author":"Chandler","year":"2017","journal-title":"Cochrane Handb Syst Rev Interv Handb Syst Rev Interv Version"},{"key":"10.1016\/j.plefa.2021.102282_bib0017","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.plefa.2021.102282_bib0018","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1161\/circ.130.suppl_2.12252","article-title":"Effects of the cholesteryl ester transfer protein inhibitor, evacetrapib, administered as monotherapy or in combination with statins on cholesterol efflux and HDL particles in patients with dyslipidemia","volume":"130","author":"Rader","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.plefa.2021.102282_bib0019","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1016\/j.jacc.2015.09.013","article-title":"Cholesterol efflux capacity and pre-beta-1 HDL concentrations are increased in dyslipidemic patients treated with evacetrapib","volume":"66","author":"Nicholls","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.plefa.2021.102282_bib0020","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.jacl.2015.11.014","article-title":"Evacetrapib alone or in combination with statins lowers lipoprotein(a) and total and small LDL particle concentrations in mildly hypercholesterolemic patients","volume":"10","author":"Nicholls","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.plefa.2021.102282_bib0021","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.arteri.2013.09.003","article-title":"Recomendaciones de la Sociedad Internacional de Aterosclerosis para el manejo de las Dislipidemias","volume":"26","author":"Mill\u00e1n N\u00fa\u00f1ez-Cort\u00e9s","year":"2014","journal-title":"Cl\u00ednica e Investig En Arterioscler"},{"key":"10.1016\/j.plefa.2021.102282_bib0022","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1194\/jlr.M018069","article-title":"Evacetrapib is a novel, potent, and selective inhibitor of cholesteryl ester transfer protein that elevates HDL cholesterol without inducing aldosterone or increasing blood pressure","volume":"52","author":"Cao","year":"2011","journal-title":"J Lipid Res"},{"key":"10.1016\/j.plefa.2021.102282_bib0023","doi-asserted-by":"crossref","first-page":"595","DOI":"10.2174\/1381612822666151125000035","article-title":"Efficacy and Safety of Evacetrapib for Modifying Plasma Lipids: a Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"22","author":"Sahebkar","year":"2016","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.plefa.2021.102282_bib0024","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/jphp.12287","article-title":"Effects of the cholesteryl ester transfer protein inhibitor evacetrapib on lipoproteins, apolipoproteins and 24-h ambulatory blood pressure in healthy adults","volume":"66","author":"Suico","year":"2014","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.plefa.2021.102282_bib0025","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.atherosclerosis.2017.04.008","article-title":"Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: the ACCENTUATE trial","volume":"261","author":"Nicholls","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.plefa.2021.102282_bib0026","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/ATVBAHA.117.309007","article-title":"Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk","volume":"37","author":"van Capelleveen","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.plefa.2021.102282_bib0027","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1056\/NEJMoa1308027","article-title":"Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease","volume":"371","author":"J\u00f8rgensen","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.plefa.2021.102282_bib0028","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1093\/eurheartj\/ehs271","article-title":"Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion","volume":"34","author":"Zheng","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.plefa.2021.102282_bib0029","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1038\/s41598-017-02601-7","article-title":"ApoCIII enrichment in HDL impairs HDL-mediated cholesterol efflux capacity","volume":"7","author":"Luo","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.plefa.2021.102282_bib0030","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.atherosclerosis.2015.12.038","article-title":"Plasma levels of apolipoprotein E and risk of ischemic heart disease in the general population","volume":"246","author":"Rasmussen","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.plefa.2021.102282_bib0031","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/0021-9150(96)05852-2","article-title":"High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport","volume":"124","author":"Assmann","year":"1996","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.plefa.2021.102282_bib0032","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/jama.1986.03380200073024","article-title":"Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study","volume":"256","author":"Castelli","year":"1986","journal-title":"JAMA"},{"key":"10.1016\/j.plefa.2021.102282_bib0033","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1161\/hc3501.095214","article-title":"Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study","volume":"104","author":"Sharrett","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.plefa.2021.102282_bib0034","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.plefa.2021.102282_bib0035","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1161\/01.ATV.20.9.2029","article-title":"CETP and atherosclerosis","volume":"20","author":"Barter","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.plefa.2021.102282_bib0036","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1161\/01.ATV.0000054658.91146.64","article-title":"Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis","volume":"23","author":"Barter","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.plefa.2021.102282_bib0037","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1161\/01.CIR.0000141730.65972.95","article-title":"Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study","volume":"110","author":"Boekholdt","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.plefa.2021.102282_bib0038","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1161\/CIRCULATIONAHA.109.875013","article-title":"Cholesteryl ester transfer protein and mortality in patients undergoing coronary angiography: the Ludwigshafen Risk and Cardiovascular Health study","volume":"121","author":"Ritsch","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.plefa.2021.102282_bib0039","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1161\/CIRCULATIONAHA.109.872705","article-title":"Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community","volume":"120","author":"Vasan","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.plefa.2021.102282_bib0040","doi-asserted-by":"crossref","first-page":"2777","DOI":"10.1001\/jama.299.23.2777","article-title":"Association of Cholesteryl Ester Transfer Protein Genotypes With CETP Mass and Activity, Lipid Levels, and Coronary Risk","volume":"299","author":"Thompson","year":"2008","journal-title":"JAMA"},{"key":"10.1016\/j.plefa.2021.102282_bib0041","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.plefa.2021.102282_bib0042","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1172\/JCI118751","article-title":"Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels","volume":"97","author":"Zhong","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.plefa.2021.102282_bib0043","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/BF02938393","article-title":"HDL metabolism and the role of HDL in the treatment of high-risk patients with cardiovascular disease","volume":"9","author":"Brewer","year":"2007","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.plefa.2021.102282_bib0044","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/CIRCRESAHA.107.161711","article-title":"Coexistence of foam cells and hypocholesterolemia in mice lacking the ABC transporters A1 and G1","volume":"102","author":"Out","year":"2008","journal-title":"Circ Res"},{"key":"10.1016\/j.plefa.2021.102282_bib0045","first-page":"3900","article-title":"Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice","volume":"117","author":"Yvan-Charvet","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.plefa.2021.102282_bib0046","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.plefa.2021.102282_bib0047","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1161\/ATVBAHA.113.301373","article-title":"Paradoxical Association of Enhanced Cholesterol Efflux With Increased Incident Cardiovascular Risks","volume":"33","author":"Li","year":"2013","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.plefa.2021.102282_bib0048","doi-asserted-by":"crossref","first-page":"625","DOI":"10.4149\/BLL_2016_121","article-title":"Unending saga of fighting cholesterol: evacetrapib is another fallen warrior","volume":"117","author":"Simko","year":"2017","journal-title":"Bratislava Med J"},{"key":"10.1016\/j.plefa.2021.102282_bib0049","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/nrcardio.2015.124","article-title":"Dysfunctional HDL and atherosclerotic cardiovascular disease","volume":"13","author":"Rosenson","year":"2016","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.plefa.2021.102282_bib0050","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/CIRCRESAHA.114.300935","article-title":"High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target","volume":"114","author":"L\u00fcscher","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.plefa.2021.102282_bib0051","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nrd2489","article-title":"Is raising HDL a futile strategy for atheroprotection?","volume":"7","author":"Joy","year":"2008","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.plefa.2021.102282_bib0052","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s11886-012-0252-3","article-title":"Evacetrapib.","volume":"14","author":"Nicholls","year":"2012","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.plefa.2021.102282_bib0053","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1177\/1074248413510784","article-title":"Evacetrapib at a Supratherapeutic Steady State Concentration Does Not Prolong QT in a Thorough QT\/QTc Study in Healthy Participants","volume":"19","author":"Suico","year":"2014","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.plefa.2021.102282_bib0054","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1056\/NEJMoa1706444","article-title":"Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease","volume":"377","year":"2017","journal-title":"N Engl J Med"}],"container-title":["Prostaglandins, Leukotrienes and Essential Fatty Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952327821000454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952327821000454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:10:18Z","timestamp":1760602218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952327821000454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5]]},"references-count":54,"alternative-id":["S0952327821000454"],"URL":"https:\/\/doi.org\/10.1016\/j.plefa.2021.102282","relation":{},"ISSN":["0952-3278"],"issn-type":[{"value":"0952-3278","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and Efficacy of Evacetrapib in Patients with Inadequately-controlled Hypercholesterolemia and High Cardiovascular Risk; A meta-analysis of Randomized Placebo-controlled Trials","name":"articletitle","label":"Article Title"},{"value":"Prostaglandins, Leukotrienes and Essential Fatty Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.plefa.2021.102282","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102282"}}